Nobel Biocare’s acquisition by Danaher finalised

Nobel Biocare has been formally acquired by Danaher after the global science and technology firm settled the public tender offer for all registered shares of Nobel Biocare Holding.

Danaher now controls approximately 97 percent of the issued registered shares of the dental products manufacturer. During the first quarter of 2015, Danaher will request the cancellation of the outstanding publicly held registered shares of Nobel Biocare.

Alternatively, Danaher may decide to initiate a squeeze-out merger of Nobel Biocare into a wholly-controlled subsidiary. In addition, the acquired company will be de-listed from the Six Swiss Exchange soon.

The takeover deal was agreed in October 2014 and has been valued at two billion Swiss francs (1.31 billion pounds). Nobel Biocare will operate as a standalone organisation within Danaher, retaining its own brand and identity. Its existing production sites and headquarters in Switzerland will also be retained.

With the completion of the acquisition, the company will become a cornerstone of the Danaher dental platform, giving the organisation a leading position in the dental implants market.